One of the first drugs that Jeff Jonas filed for approval was a Parkinson’s disease treatment. Now, a little over a quarter-century later, after executive roles at Shire and Sage Therapeutics, he’s chairing a young startup with $82 million to test whether an off-the-shelf cell therapy can treat the CNS disorder.
Kenai Therapeutics emerged Thursday with the Series A co-led by Alaska Permanent Fund Corporation, The Column Group and Cure Ventures, where Jonas is a partner.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.